Objective: To review intestinal complications associated with ibuprofen treatment of patent ductus arteriosus (PDA). Conclusion: Infants at lower GA are at risk of SIP when treated early with ibuprofen for symptomatic PDA.
Introduction
Since the identification of patent ductus arteriosus (PDA) and its association with respiratory distress syndrome in preterm infants, its prevention and/or treatment have become a significant factor in the management of preterm infants. PDA has also been strongly associated with other neonatal morbidities such as bronchopulmonary dysplasia, intraventricular hemorrhage (IVH) and necrotizing enterocolitis (NEC). 1, 2 Cyclooxygenase inhibitors such as indomethacin, and more recently ibuprofen, are commonly used for preventing or treating PDA. However, the optimal timing (prophylactic vs symptomatic treatment), dosage and benefits of medical treatment or surgical ligation have not been completely identified. Studies addressing prophylactic prevention of PDA have noted benefits of a reduced need for medical closure of PDA, decreased requirement for surgical ligation and in a decrease in the risk of more severe IVH, but have failed to show any impact on long-term neurodevelopmental outcomes. 1, 3 In the event of failure of medical treatment or contraindications, PDA is closed by surgical ligation. The latter however is associated with an increase in cardiorespiratory morbidity in the immediate postoperative period and a subsequent increased risk of bronchopulmonary dysplasia. 4 Closure of PDA for ameliorating its associated morbidities in caring for preterm neonates has therefore been considered necessary, although some have questioned this more recently. 5, 6 In the past decade, ibuprofen has been used to prevent or treat PDA with similar efficacy and a more favorable safety profile. Ibuprofen in comparison to indomethacin has been shown to have milder effects on cerebral, renal and mesenteric blood flow. 7, 8, 9 Impaired mesenteric circulation due to a 'diastolic steal' from a hemodynamically significant PDA, vasoconstrictive effects and local prostaglandin inhibition by indomethacin have been suggested as risk factors for the development of spontaneous intestinal perforation (SIP) and NEC; 10, 11 gastrointestinal complications associated with indomethacin treatment.
Intestinal perforation was first described following enteral indomethacin treatment of PDA in very low birth weight infants by Nagaraj et al. 12 However, SIP as a distinct clinical entity was described by Aschner et al., 13 who described a series of six infants with SIP with distinct clinical and radiological features and good surgical outcomes. Recent studies have shown that although SIP and NEC occur in a similar population, they differ in the timing of presentation and have distinct clinical and histological features.
14,15 SIP and NEC following ibuprofen therapy has been rarely described. 16 At our institution, we started using ibuprofen as the first line of medical therapy for the treatment of symptomatic PDA since January 2007. In this retrospective analysis, we explore the prevalence of SIP and NEC associated with ibuprofen treatment of PDA in premature infants.
Methods
Data from preterm infants treated with ibuprofen for PDA over a 32-month epoch (January 2007 to October 2009) were retrospectively reviewed for gastrointestinal complications of SIP and NEC and their associated risk factors. PDA was defined by clinical features and confirmed by echocardiography (ECHO) before initiating medical treatment. Only PDA treated with ibuprofen were included in the analyses. PDA secondary to ductaldependent cardiac lesions was excluded. PDA was reported as small, moderate or large depending on the duct size and the absence or presence of left-sided changes (left atrial enlargement and ventricular size/function). The largest size of PDA in each patient was recorded. Ibuprofen lysine was given in three doses at 10 mg kg À1 dose À1 on day 1, followed by two doses of 5 mg kg À1 dose À1 at 24-h intervals. Renal function including blood urea nitrogen, creatinine and platelet counts were monitored before each dose of ibuprofen.
Antenatal data including maternal age, race, chorioamnionitis, premature rupture of membranes and antenatal steroid use for lung maturation, and neonatal characteristics of birth weight, gender and GA were recorded. Hypotension was defined as need for fluid bolus, need for ionotrope support or need for hydrocortisone (recorded separately). Clinical morbidities of grades of IVH, periventricular leukomalacia, oxygen dependency at 28 days, retinopathy of prematurity and length of stay (LOS) were recorded. Gastrointestinal complications of spontaneous SIP 17 (defined as intestinal perforations occurring in the first 2 weeks of life and not associated with NEC or congenital anomalies) and NEC (Bell's stage II or higher) were recorded.
Data were analyzed using w 2 test and Fischer's exact test for categorical variables; Student's t-test and Wilcoxon test were used for continuous variables. Multivariate analyses with logistic regression modeling were used in a step-wise selection to identify risk factors for SIP and NEC following ibuprofen treatment. Data were analyzed using the SAS software (version 9.1). A P-value of <0.05 was considered significant.
Results
During the study period, 102 infants were treated for clinically symptomatic PDA at the discretion of the attending physician. As was our unit policy during this period, ibuprofen was exclusively used for initial medical closure of the PDA. None of these infants received prophylactic indomethacin for PDA closure or IVH prophylaxis.
Nine (9/102, 8.8%) infants developed SIP following ibuprofen treatment of PDA, whereas the remaining 93/102 (91.2%) infants did not. To determine which infants were at higher risk of developing SIP, clinical and demographic features were compared between the two groups (Tables 1 and 2 ).
The mean (±s.d.) gestational age (GA) in infants with SIP was significantly lower than that in infants without SIP (25.2 ± 1.3 vs 27.6±2.4 weeks, P ¼ 0.02). The mean (±s.d.) birth weight in infants with SIP was also lower than infants without SIP (804.4±153.3 vs 1034.7±387.2, P ¼ 0.049). There were no differences in maternal age, gender and race, premature rupture of membranes, chorioamnionitis or use of antenatal steroids for pulmonary maturation between the two groups. There were no differences in the Apgar scores at 1 and 5 min between the two groups.
The mean ( ± s.d.) age at which infants received the first dose of ibuprofen was earlier in infants with SIP (3.3 ± 1.3 vs 5.8 ± 3.5 days, P ¼ 0.03). The mean (±s.d.) age at perforation was 8.8 ± 2.7 days and occurred 3.8 ± 2.5 days after the last dose of ibuprofen. The mean (±s.d.) blood urea nitrogen, but not serum creatinine, was higher at the time of starting therapy in infants with SIP (P ¼ 0.003) ( Table 2 ). Urine output immediately Spontaneous intestinal perforation and ibuprofen R Rao et al preceding initiation, and at completion of ibuprofen treatment, was 4.4 ( ± 0.6) and 2.9 ( ± 0.7) ml À1 kg À1 h À1 in infants with SIP vs 4.1 (±1.3)and 3.5 (±1.1) ml À1 kg À1 h À1 in infants without SIP (P ¼ 0.39 and 0.2), respectively. There was no difference in the fluid intake in the immediate 24 h before initiating ibuprofen in the two groups (146.5 ( ± 27.5) vs 136.07 (±30.5) ml À1 kg À1 day
À1
, infants with SIP vs infants without SIP, P ¼ 0.9). There were no differences in the use of ionotrope, fluid bolus for hypotension or hydrocortisone use before perforation in the two groups.
The size of PDA at the time of starting treatment with ibuprofen was also not significantly different in the two groups (Table 2) . Four (4/9, 44.4%) infants in infants with SIP had large PDA and 2/9 (22.2%) had moderate sized PDA (by ECHO) after the first course of ibuprofen, whereas in the remaining, PDA had closed clinically (1, 14.3%) or by ECHO (2/7, 22.2%). Three of these four infants with large PDA subsequently had their PDA closed by surgical ligation (one before and two after SIP occurred) and none was treated with a second course of ibuprofen. In infants without SIP, 37/93 (39.8%) infants had a moderate or large PDA after the first course of ibuprofen, whereas in the remaining, 24/93 (25.8%) had clinical or ECHO (32, 34.4%) showed closure. Eight (8, 8 .3%) infants without SIP received a second course of ibuprofen and three (3.2%) infants received indomethacin for persistent PDA.
Twenty-seven (27/93, 29.0%) infants in this group had secondary PDA closure by surgical ligation.
There were no differences in the clinical outcomes of oxygen dependence at 28 days, IVH or severity of IVH, periventricular leukomalacia, retinopathy of prematurity or death in the two groups. Infants with bowel perforation stayed nearly a month longer in the NICU before discharge/death (P ¼ 0.002; Table 3 ). In multivariate analyses, higher GA was protective against developing bowel perforation; odds ratio, 95% confidence interval (OR, 95% CI) ¼ 0.26 (0.09 to 0.75), P ¼ 0.01, as was delayed treatment of PDA with ibuprofen (OR, 95% CI) ¼ 0.67 (0.41 to 0.95), P ¼ 0.03.
Infants with SIP presented with pneumoperitoneum (9/9,100%; incidental in 3/9), abdominal distension or discoloration (6/9, 66.7%), leukocytosis (2/9, 22.2%) and respiratory acidosis (1/9, 11.1%). None of the infants received significant feeds either before ibuprofen or before perforation occurred. All infants were treated surgically with bedside drains and none of them required subsequent exploratory laprotomy. One infant died at 121 and another at 236 days of age, unrelated to the initial bowel perforation.
Six (6/102, 5.9%) infants developed NEC at a median age of 32 (28 to 37) days of life. The mean (±s.d.) GA at birth was 25.8 ( ± 1.5) weeks in infants who developed NEC vs 27.5 ( ± 2.4) weeks in those who did not (P ¼ 0.08). The mean (±s.d.) birth weight in infants who developed NEC was 746.3 ( ± 131.2) vs 1031.1 (±382.1) g in those who did not (P ¼ 0.02). Four (4/6, 66.7%) infants received hydrocortisone and 3/6 (50%) received ionotrope support before ibuprofen. The use of ionotrope or hydrocortisone before ibuprofen treatment for PDA were both associated with an increased risk of NEC (P ¼ 0.05 and 0.003, respectively). The median number of ibuprofen doses and the time of starting ibuprofen doses were similar in infants who developed NEC vs those who did not (data not shown). In multivariate analyses, absence of hydrocortisone use before ibuprofen treatment When infants who developed SIP (n ¼ 9) were compared with those who developed NEC (n ¼ 6), there were no differences in the birth weight or GA between the two groups (data not shown, P ¼ NS). However, the mean age at starting ibuprofen treatment was significantly earlier in those with SIP than in those who developed NEC (3.3±1.3 vs 6.3±3.0 days, P ¼ 0.02).
We further reviewed all intestinal perforations during the study period and identified five infants with clinical features consistent with SIP. Twelve others were excluded owing to perforations associated with congenital anomalies (n ¼ 4), procedures (n ¼ 2) and perforations at referral hospital (n ¼ 6; two received prophylactic indomethacin and three were treated with ibuprofen for PDA) before transport to our hospital. In two out of these five infants, perforations occurred after being diagnosed with culturepositive sepsis (1 g negative sepsis and other had disseminated fungemia) and one infant had bacterial meningitis. There were no differences in birth weight, GA, median age at SIP (7.0 (4.5 to 8.2) days) between these five infants and those who developed perforations associated with ibuprofen treatment of PDA (data not shown). Only 1/5 had a moderate sized PDA on ECHO, but was not treated with ibuprofen owing to IVH, whereas the remaining four did not have an ECHO before SIP. All infants were hypotensive and received fluid bolus; 3/5 received hydrocortisone and 3/5 received ionotropes before perforation occurred. Four infants were treated with drains and all died, whereas one had a 'clean ileal perforation' noted at primary surgery and survived.
Discussion
The important observations from our study are that in infants with PDA treated with ibuprofen, early treatment is associated with an increased risk of SIP in the more immature infants.
SIP in preterm very low birth weight infants is clinically and histopathologically distinct from perforations associated with NEC. 18 Although NEC and SIP occur in the same population of infants, SIP occurs earlier between 4 to 14 days of age, with a peak incidence between 6 to 9 days and occurs more often in smaller and more immature infants. 14, 17, 18 The clinical characteristics of infants treated with ibuprofen and who developed SIP were similar to those described previously. 15, 17, 19, 20 Infants in our study with bowel perforation were also of younger GA, had lower birth weight and developed perforation towards the end of first week of life. All infants were treated with surgical drainage with spontaneous healing of the perforation.
SIP has been reported previously following prophylactic and symptomatic treatment of PDA with both intravenous and oral ibuprofen use. Two studies reported using prophylactic intravenous ibuprofen within 6 to 8 h after birth, with bowel perforation occurring in 8.0 to 8.3% of the infants, 8, 21 whereas another study reported bowel perforation in 8.0% when ibuprofen (treatment) was used at a median age of 6 days. 22 Bowel perforation has also been reported in isolated infants within 48 h of oral ibuprofen prophylaxis, or with treatment of PDA. 16, 23 The GA and birth weight reported in these studies are similar to our study. These and our data of the early administration of ibuprofen within the first 3 days of life and SIP are similar to the observations with indomethacin and SIP suggesting a possible link with drug metabolism (see below). 14, 15 Further, our data suggest that the incidence of SIP with ibuprofen is similar to the 2 to 8% incidence reported with indomethacin use previously. 22, 24 Although most studies have not reported the timing of perforation in relation to the medical treatment of PDA, Shorter et al. 25 noted focal perforation about 7 days following the last dose of indomethacin treatment of PDA. The mean age of first dose of indomethacin in this study was 4 days. A recent meta-analyses suggests no difference in SIP with ibuprofen compared to indomethacin, with a trend towards decreased risk with ibuprofen: (OR, 95% CI) ¼ 0.48 (0.20 to 1.14). 26 However, the total number of infants with SIP from five studies in this meta-analyses were only 6/128 (4.6%) in the ibuprofen group and 14/127 (11.0%) in the indomethacin group.
Some have questioned whether it is PDA itself and not its treatment that is the risk factor for SIP. 27 Attridge et al., 27 when analyzing infants with PDA who underwent primary ligation within the first week of life without previous exposure to indomethacin, did not note an increase in the risk of SIP, suggesting that indomethacin and not PDA was the primary risk factor. However, PDA ligation at any time (that is, even after the perforation) was associated with an increased risk of SIP. They could not distinguish whether the delayed treatment of a symptomatic PDA could result in SIP or whether SIP made PDA more resistant to closure. 27 The practice in our unit during the study was to treat symptomatic PDA and we therefore could not identify enough 'control infants' with symptomatic PDA who were not treated with ibuprofen.
Blood urea nitrogen was significantly elevated in the infants who developed SIP in our study. However, serum creatinine, fluid intake immediately preceding ibuprofen and urine output both during and after ibuprofen treatment were not different. Although ibuprofen kinetics influences the rate of PDA closure, it is independent of GA. 28 Ibuprofen clearance is dependent on postnatal age and maturation of cytochrome P450 subfamily complex. 28 The earlier initiation of ibuprofen in infants who developed SIP suggests that ibuprofen clearance and regional prostaglandin concentrations may have played a role in the development of SIP. Novack et al. 29 also noted higher blood urea nitrogen in infants with focal bowel perforation associated with indomethacin, but only after initiating treatment with indomethacin.
The increased risk of bowel perforation with elevated corticosteroid concentrations, either endogenous or exogenous (dexamethasone or hydrocortisone), particularly in the first few days of life, has been well described. 15, 20, 30 Katakam et al. 22 reported an increase in risk of SIP from 8 to 21% in infants treated with ibuprofen and hydrocortisone when compared with ibuprofen alone. However, only one infant received hydrocortisone and ibuprofen before SIP in our study. Steroids cause submucosal thinning, decreased bowel wall integrity and loss of transforming growth factor-a (an antiapoptotic factor) leading to focal bowel necrosis. 18 Simultaneous indomethacin causes depletion of intestinal nitric oxide synthatases and contractile ileus. 18 SIP is likely triggered during the recovery phase of the intestinal dysmotility induced by steroids and indomethacin. 18, 19 Whether indomethacin prophylaxis followed by treatment with either indomethacin or ibuprofen acts in a manner similar to steroids to increase the risk of SIP remains unclear. One possible explanation therefore could be that preterm infants may not have adequate protective mechanisms to maintain bowel integrity when exposed to steroids and cyclooxygenase inhibitors soon after birth.
NEC developed at a later age than those who developed SIP in our study, as has been reported previously. 31 Although some infants with SIP have been reported to occur around the same period as NEC, 15 infants in our study had the characteristic clinical features associated with NEC (Bell's stage II or higher) and thus different from SIP. The mean GA and birth weight of infants with NEC in our study were not significantly different from the ones who developed SIP. Both hydrocortisone and ionotrope exposure before ibuprofen use were identified as risk factors for infants developing NEC, suggesting that these infants were likely sicker than those who developed SIP. As indomethacin use has also been linked with NEC, 25, 32 one could also speculate that in this patient population, the timing of treatment of PDA could influence the development of SIP or NEC. In support, Shorter et al. 25 noted that in infants with SIP and NEC, infants with focal perforation received indomethacin earlier than infants who developed NEC.
In summary, our findings strongly support the association of PDA treatment with ibuprofen and SIP in premature infants p26 weeks GA, but are limited by being retrospective in nature and the lack of a true 'control' group (infants with symptomatic PDA but not treated with ibuprofen). Infants with SIP are also at an increased risk of periventricular leukomalacia and neonatal mortality. 33 In view of the recent observations of high rates of spontaneous ductal closure 34 in ELBW infants as well as concerns for the necessity for treatment of all PDA, 5, 6 we would urge caution against the early use of ibuprofen in closing symptomatic PDA in the very premature infants.
